The NIHR-supported Novavax COVID-19 vaccine is 89.3% effective at preventing COVID-19.
This is according to the interim analysis of Phase III study data, including effectiveness against the new variants of concern.
More than 1,240 Greater Manchester volunteers are taking part in the study, including almost 500 from Oldham.
The Novavax study is the largest ever double blind, placebo-controlled trial to be undertaken in the UK.
It recruited over 15,000 participants from 35 research UK sites in just over two months.
It was the first phase 3 study for the US-based biotechnology firm Novavax’s vaccine anywhere in the world.
In Greater Manchester, the study has been carried out by local research teams at two community sites.